Alnylam Pharmaceuticals
ALNY
#637
Rank
A$47.61 B
Marketcap
$367.91
Share price
1.76%
Change (1 day)
63.04%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -$6.06

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -$6.45. In 2022 the company made an earnings per share (EPS) of -$14.57 a decrease over its 2021 EPS that were of -$11.29.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-$6.06-58.44%
2022-$14.5729.03%
2021-$11.29-3.36%
2020-$11.69-8.48%
2019-$12.777.67%
2018-$11.8639.74%
2017-$8.4912.94%
2016-$7.5138.84%
2015-$5.41-32.88%
2014-$8.06259.44%
2013-$2.24-31.25%
2012-$3.2652.94%
2011-$2.1330.77%
2010-$1.63-8.77%
2009-$1.7978.13%
2008-$1.00-70.78%
2007-$3.4499.09%
2006-$1.73-43.88%
2005-$3.07-82.33%
2004-$17.40-59.23%
2003-$42.68

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-$2.67-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
$58.60-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-$12.28 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.42-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-$2.65-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
$5.87-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
$4.99-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-$3.14-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel